21 CFR 314.70 (Changes to an Approved NDA or ANDA)

21 CFR 314.70 is the FDA regulation that requires the holder of an approved New Drug Application or Abbreviated New Drug Application to classify every post-approval change — based on its potential to adversely affect the product’s identity, strength, quality, purity, or potency (ISQPP) — into one of four reporting tracks: Prior Approval Supplement, CBE-30, CBE-0, or Annual Report. ANDA holders follow the same framework: 21 CFR 314.97 requires ANDA applicants to comply with 314.70’s supplement categories, so “changes to an approved NDA” and “changes to an approved ANDA” are, procedurally, the same system.

The four reporting categories

Which category a given change falls into is not the applicant’s choice — it is determined by the nature of the change itself, as classified by the regulation and FDA’s implementing guidance (chiefly the agency’s “Changes to an Approved NDA or ANDA” guidance and product-specific annexes for biologics, sterile products, and other categories).

Prior Approval Supplement (PAS) — major changes

A PAS is required for a change with substantial potential to adversely affect the product. The applicant must submit the supplement and receive FDA approval before distributing product made using the change. Typical PAS-tier changes include a new or relocated finished-dosage-form manufacturing site, a change in the qualitative or quantitative formulation (including certain inactive-ingredient changes), a change to the drug substance synthesis route that could affect the impurity profile, a change in sterilization method or aseptic processing, and — for biologics — changes to virus removal/inactivation steps, source materials, or master cell banks. Most labeling changes that are not specifically eligible for one of the faster tracks below also require a PAS.

Changes Being Effected in 30 Days (CBE-30) — moderate-risk changes

A CBE-30 supplement covers changes with moderate potential for adverse effect. The applicant may begin distributing product made using the change 30 days after FDA receives the supplement, unless FDA notifies the applicant within that window that the supplement is deficient, that approval is required first, or otherwise objects. Examples include most specification tightening (as opposed to relaxation) that does not otherwise qualify for CBE-0, and several manufacturing-process and container-closure changes FDA’s guidance places in the moderate-risk tier rather than the major or minor tiers.

Changes Being Effected in 0 Days (CBE-0) — designated lower-risk changes

A narrower, specifically enumerated set of changes qualifies for CBE-0: the applicant may distribute product made using the change immediately upon FDA’s receipt of the supplement, with no waiting period. The best-known CBE-0 category is safety labeling: under 21 CFR 314.70(c)(6)(iii), an applicant may add or strengthen a contraindication, warning, precaution, or adverse reaction; add or strengthen a statement about drug abuse, dependence, or overdosage; add or strengthen an instruction about dosage/administration necessary for safe use; or delete false, misleading, or unsupported claims — provided there is sufficient evidence to support the change — without waiting for FDA action first. Other CBE-0 categories include specification additions or tightened in-process controls, and certain non-sterile container size/shape changes. FDA has since narrowed CBE-0 eligibility for changes to a product’s prescribing-information Highlights section specifically, which generally now require a PAS unless FDA states otherwise.

Annual Report — minor changes

Changes with only minimal potential to affect the product are not submitted as a standalone supplement at all — they are simply documented in the applicant’s next annual report to FDA under 21 CFR 314.81. Typical annual-report-tier changes include replacing manufacturing equipment with equipment of the same design and operating principle, deleting a color ingredient, extending expiration dating supported by existing long-term stability data, and purely editorial labeling revisions.

Why the distinction matters operationally

The category determines the critical-path timeline for any post-approval change: a PAS can add months of FDA review before a change may be implemented, while a properly-qualified CBE-0 change can go into effect the same day the supplement is filed. Misclassifying a change — for example, treating a manufacturing-site change as CBE-30 when it should be a PAS — risks an FDA warning letter, a requirement to cease distribution of product made under the unapproved change, or rejection of the supplement outright. Research institutions and sponsor organizations that hold NDAs/ANDAs (directly, or through a contract manufacturer or CRO acting on their behalf) typically maintain a regulatory affairs function specifically to classify and track post-approval changes against this framework, distinct from the initial approval pathway itself, which involves separate Chemistry, Manufacturing, and Controls (CMC) review during the original NDA/ANDA submission.

Worked examples

• Manufacturing site change: An NDA holder moves finished-tablet manufacturing from Facility A to a newly-qualified Facility B. Because a new manufacturing site is treated as having substantial potential to affect product quality, this requires a Prior Approval Supplement — FDA must approve the new site (which typically includes a facility inspection) before product from Facility B can be distributed.
• Safety labeling update: Post-marketing surveillance under 21 CFR 314.80 generates evidence of a previously unlisted adverse reaction with sufficient causal evidence. The applicant adds the reaction to the Warnings and Precautions section and may distribute the updated labeling immediately via a CBE-0 supplement, without waiting for FDA to act on it first.

Counter-example

Simply updating internal batch records, SOPs, or a contract manufacturer’s own internal quality documentation — with no change to the approved product’s formulation, manufacturing process, specifications, or labeling — is not a 314.70 event at all. 314.70 governs changes to what was actually approved in the NDA/ANDA; purely internal documentation housekeeping that doesn’t alter the approved product or process falls outside the supplement system entirely (though it may still be subject to GMP recordkeeping requirements).

Related CASRAI content

See also 21 CFR 314.80 (Postmarketing Reporting of Adverse Drug Experiences) for the ongoing post-marketing safety-reporting obligation that often generates the evidence behind a CBE-0 safety labeling change; the Good Manufacturing Practice (GMP) guide for the quality-system context manufacturing-site and process changes sit within; the Clinical Trial Supply Management guide for pre-approval investigational-product manufacturing and distribution controls; and the Clinical Trial Phases guide for where NDA/ANDA approval sits in the overall development timeline. For the broader regulatory-compliance context, see the Clinical Research Administration pillar.